Trusted Resource for Clinical Trials, Protocols & Progress
Pediatric clinical trials in India are gradually evolving to meet the complex demands of child-specific drug development and public health needs. While regulatory clarity and infrastructure improvements are ongoing, a combination of robust ethics, targeted site preparation, and community engagement will determine the success and ethical integrity of these vital studies.
Click to read the full article.
Sponsors should: (1) submit detailed meeting packages; (2) craft focused regulatory questions; (3) prepare multidisciplinary teams; (4) align internal decision-making before meetings; (5) document FDA responses carefully; (6) engage regulatory experts; (7) consider mock rehearsals; (8) maintain respectful and collaborative interactions; (9) follow up promptly with meeting minutes; and (10) integrate FDA advice into global strategy.
Click to read the full article.
Data integrity issues remain a top focus of MHRA inspections in UK clinical trials. By understanding common pitfalls, addressing root causes, and adopting robust oversight mechanisms, sponsors, CROs, and NHS Trusts can safeguard trial credibility. A proactive, problem–solution approach ensures that data remain reliable, regulatory-compliant, and fit for global submissions.
Click to read the full article.
MRCTs with EU sites must account for:
Rare Diseases: EU Reference Networks facilitate recruitment across borders.
Oncology: EU sites are highly sought after for Phase III oncology trials due to strong infrastructure.
ATMPs: Gene and cell therapy trials require EMA CAT oversight, adding complexity.
Decentralized Trials: Hybrid models help reach broader populations but raise additional compliance requirements.
COVID-19 was a turning point for India’s clinical trial ecosystem. What began as a disruption led to accelerated digitalization, decentralized trial models, and streamlined regulatory pathways. Many of these changes — remote monitoring, hybrid site visits, digital consent — are here to stay and will define the next era of clinical research operations in India.
Click to read the full article.
Sponsors should: (1) validate digital tools thoroughly; (2) engage FDA early to discuss digital endpoint proposals; (3) ensure data integrity and cybersecurity compliance; (4) incorporate patient feedback in endpoint selection; (5) establish SOPs for device use and troubleshooting; (6) monitor patient adherence; (7) conduct pilot studies before pivotal trials; (8) document all validation studies; (9) align SAPs with digital endpoints; and (10) maintain inspection-ready data systems.
Click to read the full article.
UK clinical trial transparency obligations post-Brexit are evolving toward a more independent system, while still aligned with global expectations. Sponsors must manage fragmented registry requirements, stricter enforcement by HRA, and the need for plain language communication. Early planning, strong CRO support, and proactive dialogue with regulators are essential to maintain compliance and public confidence in the UK research environment.
Click to read the full article.
Special contexts where eConsent is impactful include:
Rare Diseases: Digital platforms help reach geographically dispersed patients.
Pediatrics: Multimedia content supports age-appropriate comprehension for minors and guardians.
Oncology Trials: Complex consent forms benefit from simplified digital tools with embedded FAQs.
Decentralized Trials: Remote recruitment and monitoring rely heavily on eConsent for compliance.
Sponsors and investigators should: (1) establish centralized IRB review; (2) implement harmonized SOPs across sites; (3) invest in electronic data management systems; (4) apply risk-based monitoring; (5) train all staff in GCP; (6) plan realistic recruitment strategies; (7) engage patient advocacy groups; (8) foster collaboration across institutions; (9) secure sustainable funding; and (10) maintain inspection readiness across all participating sites.
Click to read the full article.
India is at the cusp of a digital revolution in clinical research. While challenges around infrastructure, literacy, and regulation persist, the benefits of digital health and decentralized trial models are undeniable. With continued regulatory clarity and stakeholder training, India can emerge as a global leader in hybrid and decentralized clinical trial operations.
Click to read the full article.
